GlassScriptPhysician profile
Lauren A Willmer
NPI 1316389323
$6,934.84
in general payments reported to CMS, 2019-2025
33 companies · $1,396 in 2025
The $1,396 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $828 · 2022: $1,145 · 2023: $2,033 · 2024: $1,533 · 2025: $1,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,962.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,524.95 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $935.74 | 2021-2025 | |
| Novo Nordisk INC | $694.60 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $478.12 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $475.97 | 2021-2025 | Trintellix |
| Lilly USA, LLC | $433.56 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $430.55 | 2021-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $419.49 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $187.02 | 2022-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $178.67 | 2022-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $164.47 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.65 | 2021-2023 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $143.71 | 2022-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $140.77 | 2022 | |
| Abbott Laboratories | $109.24 | 2022-2025 | Freestyle Libre 3 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $77.28 | 2022-2023 | Quviviq |
| Lundbeck LLC | $65.86 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $49.94 | 2022 | |
| Phathom Pharmaceuticals, INC. | $34.17 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $29.31 | 2023-2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $25.86 | 2022-2023 | Verquvo, Belsomra |
| Radius Health, INC. | $25.81 | 2023 | Tymlos |
| Sanofi Pasteur INC. | $23.82 | 2023 | |
| Eisai INC. | $19.44 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.38 | 2022 | |
| Horizon Therapeutics Plc | $15.45 | 2021 | |
| Nestle Healthcare Nutrition INC. | $14.73 | 2021 | |
| Almatica Pharma LLC | $14.69 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.56 | 2024 | Gvoke Hypopen |
| Boston Scientific Corporation | $12.62 | 2022 | |
| Esperion Therapeutics, INC. | $12.04 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.83 | 2022 | |
| Genentech USA, INC. | $7.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Willmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.